Alpha 2.0
Login Register
» Articles » PMID: 37122438

Entrectinib Use in a Platinum-refractory Mucinous Ovarian Cancer Harboring a NTRK3 Gene Fusion

Overview
Journal Gynecol Oncol Rep
Publisher Elsevier
Date 2023 May 1
PMID 37122438
Authors
Olivia G Beck
Melissa M Hardesty
Affiliations
Soon will be listed here.
Abstract

Ovarian cancer is difficult to treat, and the mucinous epithelial subtype has a particularly poor response to traditional chemotherapy regimens. Entrectinib is a tumor-agnostic tyrosine kinase inhibitor with limited data regarding its use in ovarian cancers, though it demonstrates significant tumor response and patient tolerability in other settings. Here we outline what we believe to be the first case in which Entrectinib was successfully utilized to treat a patient with mucinous ovarian cancer. A 51-year-old woman with stage IVB mucinous ovarian cancer possessing a KANK1-NTRK3 gene fusion experienced tumor progression and clinical deterioration with conventional chemotherapeutics. Upon initiation of Entrectinib treatment she experienced rapid clinical improvement, with significant partial response and sustained decrease in tumor markers.

References
1.
Harbin L, Gallion H, Allison D, Kolesar J . Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer-An Opportunity for Targeted Therapy. Diagnostics (Basel). 2022; 12(4). PMC: 9030726. DOI: 10.3390/diagnostics12040842. View
2.
Elias K, Guo J, Bast Jr R . Early Detection of Ovarian Cancer. Hematol Oncol Clin North Am. 2018; 32(6):903-914. PMC: 6376972. DOI: 10.1016/j.hoc.2018.07.003. View
3.
Endo Y, Watanabe T, Saito M, Saito K, Suzuki R, Sano H . A rare case of recurrent ovarian cancer with gene rearrangement: A case report. Mol Clin Oncol. 2022; 16(4):90. PMC: 8892455. DOI: 10.3892/mco.2022.2523. View
4.
Bamias A, Psaltopoulou T, Sotiropoulou M, Haidopoulos D, Lianos E, Bournakis E . Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer. 2010; 116(6):1462-8. DOI: 10.1002/cncr.24915. View
5.
Meagher N, Schuster K, Voss A, Budden T, Pang C, DeFazio A . Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. Gynecol Oncol. 2018; 150(3):527-533. DOI: 10.1016/j.ygyno.2018.07.013. View